Xueshuantong improves cerebral microcirculation disorder: action mechanism based on network pharmacology and experimental validation
10.16438/j.0513-4870.2021-1858
- VernacularTitle:基于网络药理学和实验验证的血栓通改善缺血性脑微循环障碍作用机制研究
- Author:
Gao-rui WANG
1
;
Zi-yu CHEN
1
;
Hui WU
1
;
Ying-ping LIU
1
;
Ming CHEN
2
;
Shu-sheng LAI
2
;
Xiao-jun WU
1
;
Zheng-tao WANG
1
Author Information
1. Institute of Chinese Materia Medica of Shanghai University of Traditional Chinese Medicine and Shanghai Key Laboratory of Compound Chinese Medicines, Shanghai 201203, China
2. Guangxi Key Laboratory of Comprehensive Utilization Technology of Pseudo-ginseng, Wuzhou 543002, China
- Publication Type:Research Article
- Keywords:
network pharmacology;
Xueshuantong;
notoginsenoside;
cerebral ischemia;
brain microcirculation disorder
- From:
Acta Pharmaceutica Sinica
2022;57(7):2077-2086
- CountryChina
- Language:Chinese
-
Abstract:
This study is to explore the mechanism of Xueshuantong improving cerebral microcirculation disorder through the combination of network pharmacology and experimental validation in vivo. Structural formulas of main Panax notoginseng saponins, including notoginsenoside R1, and ginsenoside Rg1, Re, Rb1 and Rd were obtained from Pubchem website and their potential targets were predicted by Swiss Target Prediction database. Potential molecular targets of brain microcirculation disorder were acquired from OMIM and GeneCards database. The overlapped molecular targets between the drug and disease were analyzed. Protein interaction analysis and topology maps were constructed through the STRING online analysis platform and Cytoscape software. Core action targets were selected. GO function and KEGG pathway were analyzed by DAVID database. Immunohistochemical method was used to examine the expression of platelet endothelial cell adhesion molecule-1 (CD31) in the ischemic cortex of middle cerebral artery occlusion and reperfusion (MCAO/R) rats. The levels of mRNA and protein expressions of core action targets in MCAO/R model rats′ brain microvessels were verified by RT-qPCR and Western blot. Based on network pharmacology, 242 targets of Xueshuantong, 425 targets of brain microcirculation disorder, and 35 overlapped targets were obtained. The potential key targets of Xueshuantong, protein kinase B (AKT1), vascular endothelial growth factor A (VEGFA), caspase 3 (CASP3), matrix metallopeptidase 9 (MMP-9), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), signal transducer and activator of transcription 3 (STAT3) involved in the alleviation of cerebral microcirculation disorder were obtained by setting degree and betweenness centrality as screening parameters. Xueshuantong at the dose of 48 mg·kg-1 was shown to significantly improve the injury of neurological behaviors, as well as the density and morphology of microvessels of MCAO/R model rats. Xueshuantong could down-regulate the mRNA levels of AKT1, MMP-9, and STAT3, increase the protein expression levels of CD31, phosphorylated AKT and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and the ratio of B-cell lymphoma 2/Bcl-2-associated X (Bcl-2/Bax), but decrease the protein expression levels of MMP-9, cleaved caspase-3 and phosphorylated STAT3. In summary, Xueshuantong could improve ischemic cerebral microcirculation disorder and thereby reduce nerve damage in ischemia-reperfusion rats by regulating signaling pathways related with PI3K, AKT, MMP-9, STAT3 and caspase-3 in microvessels. The study strictly adhered to all ethical protocols that experimental animals should follow in the course of medical research.
